MML Investors Services LLC Sells 1,519 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

MML Investors Services LLC trimmed its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 10.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,631 shares of the company’s stock after selling 1,519 shares during the period. MML Investors Services LLC’s holdings in Apellis Pharmaceuticals were worth $393,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals during the 3rd quarter worth about $27,000. True Wealth Design LLC acquired a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $27,000. Capital Performance Advisors LLP bought a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $56,000. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares in the last quarter. Finally, nVerses Capital LLC raised its position in Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

APLS has been the topic of a number of recent research reports. Mizuho decreased their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. William Blair began coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating for the company. HC Wainwright dropped their price objective on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. JPMorgan Chase & Co. reduced their target price on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, September 13th. Finally, The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $49.94.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $33.21 on Tuesday. The firm has a market capitalization of $4.13 billion, a P/E ratio of -16.36 and a beta of 0.94. The firm’s 50-day moving average price is $30.43 and its 200-day moving average price is $34.44. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the previous year, the company posted ($1.17) EPS. The firm’s revenue was up 78.3% on a year-over-year basis. Equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).